IRADIMED CORPORATION (IRMD) SEC Filings & Earnings Calls
EquiReason read 10 IRADIMED CORPORATION SEC filings in the last 12 months. Latest: 8-K on 2026-07-31 — IRADIMED CORPORATION filed an 8-K under Item 2.02 announcing financial results for the quarter ended June 30, 2026. The press release is furnished as Exhibit 99.1..
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
- Market cap
- 1.1B
- P/E TTM
- 47.9
- Dividend yield
- 0.9%
- 52-week
- —
- Next earnings
- 29 Oct, in 5 days
Every filing, read
last 12 months · SECWhat happened, the numbers inside, guidance and risks. The original is one click away.
31 Jul 202610-QQuarterly revenue flat, gross margin declined due to new product inefficiencies, but international and disposables grew.earningsopen
Figures in the filing · each found in the filing text
| Revenue · Q2-2026 | $20M | +1% y/y |
| Gross profit percentage · Q2-2026 | 74.0% | |
| Net income · Q2-2026 | $5M | -10% y/y |
| Cash and cash equivalents · Q2-2026 | $59M |
Risks flagged
Gross margin pressure from new product ramp
“The decrease in gross margin is attributed to initial production inefficiencies on new product manufacturing.” · word for word
Domestic revenue decline
“Revenue from sales in the U.S. decreased by $1.5 million, or 8%, to $16.7 million for the three months ended June 30, 2026, from $18.2 million for the same period in 2025.” · word for word
1 May 202610-QRevenue $22M (+13% y/y); Gross Profit Percentage 77; Cash and cash equivalents $56Mopen
Figures in the filing · each found in the filing text
| Revenue · Q1-2026 | $22M | +13% y/y |
| Gross Profit Percentage · Q1-2026 | 77.0% | |
| Cash and cash equivalents · 2026-03-31 | $56M | |
| Operating cash flow · Q1-2026 | $8M | +93% y/y |
Risks flagged
Concentration on limited product line
“our primary reliance on a limited number of products” · word for word
Regulatory clearance dependency
“our ability to receive 510(k) clearance for our products and product candidates” · word for word
1 May 20268-K · 2.02Revenue $22M (+13% y/y); GAAP diluted EPS $0.45 (+22% y/y); Non-GAAP diluted EPS $0.49 (+17% y/y); Guidance: FY2026 revenue $91M-$96M, GAAP EPS $1.90-$2.05, non-GAAP EPS $2.06-$2.21earningsopen
Figures in the filing · each found in the filing text
| Revenue · Q1-2026 | $22M | +13% y/y |
| GAAP diluted EPS · Q1-2026 | $0.45 | +22% y/y |
| Non-GAAP diluted EPS · Q1-2026 | $0.49 | +17% y/y |
| Operating income · Q1-2026 | $7M | +33% y/y |
| Net income · Q1-2026 | $6M | +24% y/y |
| Gross profit margin · Q1-2026 | 77.0% | |
| Operating cash flow · Q1-2026 | $8M | +93% y/y |
| MRI Compatible IV Infusion Pump Systems revenue · Devices · Q1-2026 | $8M | +28% y/y |
| MRI Compatible Patient Vital Signs Monitoring Systems revenue · Devices · Q1-2026 | $7M | +9% y/y |
| Disposables revenue · Disposables · Q1-2026 | $5M | -1% y/y |
Guidance
FY2026 revenue $91M-$96M, GAAP EPS $1.90-$2.05, non-GAAP EPS $2.06-$2.21
Full-year guidance reaffirmed; Q2 guidance provided; new product launch expected to drive growth in H2.
30 Apr 2026DEF 14AProxy statement for 2026 annual meeting, including director elections, auditor ratification, and advisory say-on-pay vote.open
Figures in the filing · each found in the filing text
| Revenue · FY2025 | $84M | |
| Net income · FY2025 | $22M | |
| Cash and cash equivalents · 2025-12-31 | $51M | |
| Dividends paid · FY2025 | $15M | |
| Capital expenditures · FY2025 | $8M | |
| General and administrative expenses · FY2025 | $18M | |
| Research and development expenses · FY2025 | $3M | |
| Sales and marketing expenses · FY2025 | $17M | |
| CEO base salary · FY2025 | $375107.00 | |
| CEO bonus · FY2025 | $395000.00 |
10 Feb 20268-K · 2.02Revenue $23M (+17% y/y); GAAP diluted EPS $0.50 (+25% y/y); Non-GAAP diluted EPS $0.54 (+23% y/y); Guidance: FY2026 revenue $91-96M; GAAP diluted EPS $1.90-2.05; non-GAAP diluted EPS $2.06-2.21earningsopen
Figures in the filing · each found in the filing text
| Revenue · Q4-2025 | $23M | +17% y/y |
| GAAP diluted EPS · Q4-2025 | $0.50 | +25% y/y |
| Non-GAAP diluted EPS · Q4-2025 | $0.54 | +23% y/y |
| Net income · Q4-2025 | $6M | +25% y/y |
| Non-GAAP net income · Q4-2025 | $7M | +23% y/y |
Guidance
FY2026 revenue $91-96M; GAAP diluted EPS $1.90-2.05; non-GAAP diluted EPS $2.06-2.21
Guidance implies continued growth driven by new product launch; dividend increase signals confidence.
Risks flagged
Product launch dependency: next-generation 3870 pump rollout expected to accelerate in H2 2026; any delays could impact revenue.
“Full rollout of next-generation 3870 MRI-compatible IV infusion pump expected to begin in Q1 2026, with real acceleration and meaningful revenue contribution expected in the second half of the year”
8 Dec 20258-K · 8.01Special Dividend per Share $0.50open
Figures in the filing · each found in the filing text
| Special Dividend per Share · 2025-12-30 | $0.50 |
3 Nov 202510-QIRADIMED reported Q3 2025 revenue of $21.2M (+16% YoY) and net income of $5.6M (+12% YoY), with gross margin expansion to 78% and strong domestic growth.earningsopen
Figures in the filing · each found in the filing text
| Revenue · Q3-2025 | $21M | +16% y/y |
| Gross Margin · Q3-2025 | 78.0% | |
| Net Income · Q3-2025 | $6M | +12% y/y |
| Diluted EPS (GAAP) · Q3-2025 | $0.43 | +8% y/y |
| Revenue · 9M-2025 | $61M | +13% y/y |
| Cash and Cash Equivalents · Q3-2025 | $57M | |
| Operating Cash Flow · 9M-2025 | $19M | -3% y/y |
| U.S. Revenue · United States · Q3-2025 | $18M | +19% y/y |
| U.S. Revenue · United States · 9M-2025 | $52M | +18% y/y |
Guidance
Expect higher revenue and higher operating expenses for remainder of FY2025 vs same period 2024
Management expects higher revenue in the remainder of FY2025 compared to the same period in 2024, driven by continued demand, but also higher operating expenses.
Risks flagged
International Revenue Decline
“Revenue from sales internationally decreased by $0.9 million, or 9%, for the nine months ended September 30, 2025 to $8.9 million, from $9.8 million for the same period in 2024.” · word for word
Dependence on GPO Agreements
“Under our GPO agreements, we are required to pay the GPOs a fee of three percent of the sales of our products to members of the GPO.” · word for word
3 Nov 20258-K · 2.02Revenue $21M (+16% y/y); GAAP Diluted EPS $0.43 (+8% y/y); Non-GAAP Diluted EPS $0.47 (+9% y/y); Guidance: FY2025 revenue guidance raised to $82.5M-$83.5M; GAAP EPS to $1.68-$1.72earningsopen
Figures in the filing · each found in the filing text
| Revenue · Q3-2025 | $21M | +16% y/y |
| GAAP Diluted EPS · Q3-2025 | $0.43 | +8% y/y |
| Non-GAAP Diluted EPS · Q3-2025 | $0.47 | +9% y/y |
| Gross Margin · Q3-2025 | 78.0% | |
| Net Income · Q3-2025 | $6M | +10% y/y |
| Operating Cash Flow · Q3-2025 | $7M | -23% y/y |
| Dividend per Share · Q4-2025 | $0.17 |
Guidance
FY2025 revenue guidance raised to $82.5M-$83.5M; GAAP EPS to $1.68-$1.72
Raised full-year guidance on record revenue and strong backlog.
Risks flagged
Operating cash flow declined 23% YoY due to working capital timing.
“cash flow from operations was $7.0 million, compared to $9.1 million for the comparable period of 2024, a decrease of 23%” · word for word
IRADIMED CORPORATION — questions
- What did IRADIMED CORPORATION file recently?
- 10 SEC filings in the last 12 months. Latest: 8-K on 2026-07-31 — IRADIMED CORPORATION filed an 8-K under Item 2.02 announcing financial results for the quarter ended June 30, 2026. The press release is furnished as Exhibit 99.1.
Every figure on this page comes from IRADIMED CORPORATION's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.